These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29684141)

  • 41. Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16.
    Mbunkah HA; Marzel A; Schmutz S; Kok YL; Zagordi O; Shilaih M; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Kouyos RD; Günthard HF; Metzner KJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1917-1929. PubMed ID: 29635462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).
    Machado DM; Fernandes SC; Succi RC; Freire WS; Pannuti CS; Gouveia AB; Levi JE; Diaz RS
    Rev Inst Med Trop Sao Paulo; 2005; 47(1):1-5. PubMed ID: 15729467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis.
    Sotillo A; Sierra O; Martínez-Prats L; Gutiérrez F; Zurita S; Pulido F; Rubio R; Delgado R
    J Virol Methods; 2018 Oct; 260():1-5. PubMed ID: 29969601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.
    Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO
    J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
    Ghosn J; Wirden M; Ktorza N; Peytavin G; Aït-Mohand H; Schneider L; Dominguez S; Bricaire F; Calvez V; Costagliola D; Katlama C
    AIDS; 2005 Oct; 19(15):1643-7. PubMed ID: 16184034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort.
    Stekler JD; Milne R; Payant R; Beck I; Herbeck J; Maust B; Deng W; Tapia K; Holte S; Maenza J; Stevens CE; Mullins JI; Collier AC; Frenkel LM
    PLoS Med; 2018 Mar; 15(3):e1002537. PubMed ID: 29584723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trends in Drug Resistance Prevalence, HIV-1 Variants and Clinical Status in HIV-1-infected Pediatric Population in Madrid: 1993 to 2015 Analysis.
    Rojas Sánchez P; Domínguez S; Jiménez De Ory S; Prieto L; Rojo P; Mellado P; Navarro M; Delgado R; Ramos JT; Holguín Á;
    Pediatr Infect Dis J; 2018 Mar; 37(3):e48-e57. PubMed ID: 28991889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Community HIV-1 drug resistance is associated with transmitted drug resistance.
    Tilghman MW; Pérez-Santiago J; Osorio G; Little SJ; Richman DD; Mathews WC; Haubrich RH; Smith DM
    HIV Med; 2014 Jul; 15(6):339-46. PubMed ID: 24417811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
    Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
    J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
    Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
    Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.
    Bezemer D; de Ronde A; Prins M; Porter K; Gifford R; Pillay D; Masquelier B; Fleury H; Dabis F; Back N; Jurriaans S; van der Hoek L;
    Antivir Ther; 2006; 11(2):173-8. PubMed ID: 16640098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART.
    Vazquez-Guillen JM; Palacios-Saucedo GC; Rivera-Morales LG; Garcia-Campos J; Ortiz-Lopez R; Noguera-Julian M; Paredes R; Vielma-Ramirez HJ; Ramirez TJ; Chavez-Garcia M; Lopez-Guillen P; Briones-Lara E; Sanchez-Sanchez LM; Vazquez-Martinez CA; Rodriguez-Padilla C
    PLoS One; 2016; 11(1):e0147591. PubMed ID: 26807922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management.
    Bon I; Alessandrini F; Borderi M; Gorini R; Re MC
    New Microbiol; 2007 Jul; 30(3):313-7. PubMed ID: 17802917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences.
    Lipscomb JT; Switzer WM; Li JF; Masciotra S; Owen SM; Johnson JA
    J Infect Dis; 2014 Dec; 210(11):1827-37. PubMed ID: 24924164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.